Piel, F.B., et al., Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med, 2013. 10(7): p. e1001484.CrossRefGoogle ScholarPubMed

Charache, S., et al., Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med, 1995. 332(20): p. 1317–1322.CrossRefGoogle ScholarPubMed

Fitzhugh, C.D., et al., Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol Oncol Clin North Am, 2014. 28(6): p. 1171–85.CrossRefGoogle ScholarPubMed

Adams, R.J., et al., Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography [see comments]. N Engl J Med, 1998. 339(1): p. 5–11.CrossRefGoogle ScholarPubMed

Kwiatkowski, J.L., et al., Effect of transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 56(5): p. 777–782.CrossRefGoogle Scholar

Fitzhugh, C.D., et al., Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol, 2010. 85(1): p. 36–40.CrossRefGoogle ScholarPubMed

Platt, O.S., et al., Mortality in sickle cell disease. Life expectancy and risk factors for early death [see comments]. N Engl J Med, 1994. 330(23): p. 1639–44.CrossRefGoogle ScholarPubMed

Johnson, F.L., et al., Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med, 1984. 311(12): p. 780–3.CrossRefGoogle Scholar

Vermylen, C. and Cornu, G., Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol, 1994. 16(1): p. 18–21.Google ScholarPubMed

Bernaudin, F., et al., Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO. Bone Marrow Transplant, 1993. 12(Suppl 1): p. 118–21.Google Scholar

Walters, M.C., et al., Bone marrow transplantation for sickle cell disease. N Engl J Med, 1996. 335(6): p. 369–76.CrossRefGoogle ScholarPubMed

Walters, M.C., et al., Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood, 2000. 95(6): p. 1918–24.Google ScholarPubMed

Vermylen, C. and Cornu, G., Hematopoietic stem cell transplantation for sickle cell anemia. Curr Opin Hematol, 1997. 4(6): p. 377–80.CrossRefGoogle ScholarPubMed

Bernaudin, F., et al., Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood, 2007. 110(7): p. 2749–56.CrossRefGoogle ScholarPubMed

Walters, M.C., et al., Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant, 2010. 16(2): p. 263–72.CrossRefGoogle ScholarPubMed

Kuentz, M., Peripheral blood stem cell allograft from HLA-unrelated donors. Hematol Cell Ther, 1996. 38(5): p. 453–4.Google ScholarPubMed

Hsieh, M.M., et al., Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA, 2014. 312(1): p. 48–56.CrossRefGoogle ScholarPubMed

Iannone, R., et al., Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant, 2003. 9(8): p. 519–28.CrossRefGoogle ScholarPubMed

Horan, J.T., et al., Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant, 2005. 35(2): p. 171–7.CrossRefGoogle ScholarPubMed

Walters, M.C., et al., Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant, 1996. 2(2): p. 100–4.Google ScholarPubMed

Liem, R.I., et al., Parental attitudes toward research participation in pediatric sickle cell disease. Pediatr Blood Cancer, 2010. 55(1): p. 129–33.CrossRefGoogle ScholarPubMed

Locatelli, F., et al., Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood, 2013. 122(6): p. 1072–8.CrossRefGoogle ScholarPubMed

Ruggeri, A., et al., Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant, 2011. 17(9): p. 1375–82.CrossRefGoogle ScholarPubMed

Kamani, N.R., et al., Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant, 2012. 18(8): p. 1265–72.CrossRefGoogle ScholarPubMed

Krishnamurti, L., et al., Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant, 2003. 31(7): p. 547–50.CrossRefGoogle ScholarPubMed

Hsieh, M., Wilder, J., Fitzhugh, C., Link, B., Tisdale, J.F.. Results of Alternative Donor Search in Adult Patients with Severe Sickle Cell Disease (SCD) Eligible for Hematopoietic Stem Cell Transplantation (HSCT). The American Society of Hematology Annual Meeting. 2007.CrossRefGoogle Scholar

Bolanos-Meade, J., et al., HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood, 2012. 120(22): p. 4285–91.CrossRefGoogle ScholarPubMed

Dallas, M.H., et al., Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant, 2013. 19(5): p. 820–30.CrossRefGoogle ScholarPubMed

Cavazzana-Calvo, M., et al., Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [see comments]. Science, 2000. 288(5466): p. 669–72.CrossRefGoogle ScholarPubMed

Aiuti, A., et al., Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med, 2002. 8(5): p. 423–5.CrossRefGoogle ScholarPubMed

Aiuti, A., et al., Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 2002. 296(5577): p. 2410–3.CrossRefGoogle ScholarPubMed

Ott, M.G., et al., Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006. 12(4): p. 401–9.CrossRefGoogle ScholarPubMed

Aiuti, A., et al., Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest, 2007. 117(8): p. 2233–40.CrossRefGoogle ScholarPubMed

Aiuti, A., et al., Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med, 2009. 360(5): p. 447–58.CrossRefGoogle ScholarPubMed

Gaspar, H.B., et al., Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med, 2011. 3(97): p. 97ra80.CrossRefGoogle ScholarPubMed

Hacein-Bey-Abina, S., et al., Efficacy of gene therapy for X-linked severe combined immunodeficiency. New Engl J Med, 2010. 363(4): p. 355–64.CrossRefGoogle ScholarPubMed

Hacein-Bey-Abina, S., et al., A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. New Engl J Med, 2014. 371(15): p. 1407–17.CrossRefGoogle ScholarPubMed

May, C., et al., Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature, 2000. 406(6791): p. 82–6.CrossRefGoogle ScholarPubMed

Persons, D.A., et al., Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood, 2003. 102(2): p. 506–13.CrossRefGoogle ScholarPubMed

Persons, D.A., et al., The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood, 2003. 101(6): p. 2175–83.CrossRefGoogle ScholarPubMed

Pawliuk, R., et al., Correction of sickle cell disease in transgenic mouse models by gene therapy. Science, 2001. 294(5550): p. 2368–71.CrossRefGoogle ScholarPubMed

Imren, S., et al., Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A, 2002. 99(22): p. 14380–5.CrossRefGoogle ScholarPubMed

Moreau-Gaudry, F., et al., High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood, 2001. 98(9): p. 2664–72.CrossRefGoogle ScholarPubMed

Perumbeti, A., et al., A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood, 2009. 114(6): p. 1174–85.CrossRefGoogle Scholar

Arumugam, P.I., et al., Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther, 2007. 15(10): p. 1863–71.CrossRefGoogle ScholarPubMed

Takahashi, K. and Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663–76.CrossRefGoogle ScholarPubMed

Gaj, T., Gersbach, C.A., and Barbas, C.F. 3rd, ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 2013. 31(7): p. 397–405.CrossRefGoogle ScholarPubMed

Ballas, S.K., The cost of health care for patients with sickle cell disease. Am J Hematol, 2009. 84(6): p. 320–2.CrossRefGoogle ScholarPubMed

Arnold, S.D., et al., Allogeneic hematopoietic cell transplantation for children with sickle cell disease is beneficial and cost-effective: a single-center analysis. Biol Blood Marrow Transplant, 2015. 21(7): p. 1258–65.CrossRefGoogle ScholarPubMed

Saenz, C. and Tisdale, J.F., Assessing costs, benefits, and risks in chronic disease: taking the long view. Biol Blood Marrow Transplant, 2015. 21(7): p. 1149–50.CrossRefGoogle ScholarPubMed